What is risk-based monitoring under ICH E6(R3)?

Risk-based monitoring means the sponsor decides how much monitoring a trial needs, and what kind, from the risks that trial actually carries, rather than checking every data point at every site (ICH E6(R3) 3.11.4).

E6(R3) lets the sponsor combine on-site, remote and centralized monitoring, written into a monitoring plan that focuses on what is critical to quality, especially participant safety and the primary endpoints (ICH E6(R3) 3.11.4.3).

The building blocks

  • Site monitoring, on site or remote, including secure read-only access to source records where appropriate (ICH E6(R3) 3.11.4.1).
  • Centralized monitoring: timely review of accumulated data by qualified people such as medical monitors and data scientists, which can reduce site visits or stand on its own (ICH E6(R3) 3.11.4.2).
  • A monitoring plan that names the strategy, methods, tools and the reasons for them (ICH E6(R3) 3.11.4.3).
  • Frequency set by identified risks and changed as knowledge accumulates (ICH E6(R3) 3.11.4.1).

What drives the risk assessment

The guideline lists the trial's objective, design, complexity, blinding, number of participants, investigational product, current knowledge of its safety and the endpoints as factors in the extent and nature of monitoring (ICH E6(R3) 3.11.4). Behind it sit two principles: quality built into the design (ICH E6(R3) Principle 6) and processes proportionate to the risks to participants and the reliability of results (ICH E6(R3) Principle 7).

What it means for sites

Fewer full source data verification visits does not mean less scrutiny. Centralized analytics can flag a site for data patterns, deviations or late safety reports, and the site then gets targeted monitoring (ICH E6(R3) 3.11.4.2). Sites with staff who handle consent, eligibility and safety reporting well from the start generate fewer signals.

Sponsors and CROs also look at site staff readiness before a study starts. The Study Start Readiness Check gives a sponsor a readiness record for the staff named on a study, and sites keep the underlying training records in the free Site Portal.

Questions people also ask

Is full source data verification required?

No. The sponsor determines the extent and nature of monitoring based on identified risks (ICH E6(R3) 3.11.4).

What is centralized monitoring?

An evaluation of accumulated data, performed in a timely manner by the sponsor's qualified people, such as a medical monitor, data manager or biostatistician (ICH E6(R3) 3.11.4.2).

What are key risk indicators?

Metrics, such as deviation rates or late data entry, that a sponsor tracks across sites to target monitoring. E6(R3) does not prescribe them; they are one way to put centralized monitoring into practice.

Who can perform monitoring?

People who are not involved in the clinical conduct of the trial at the site being monitored; some activities may be done by people in different roles, such as a data scientist (ICH E6(R3) 3.11.4).

Primary sources

  • ICH E6(R3) Guideline for Good Clinical Practice, final version adopted 6 January 2025 (ICH): https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
  • E6(R3) Good Clinical Practice, final guidance (U.S. Food and Drug Administration): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp

Last reviewed

2026-11-12